Sun Y - Search Results

1

SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study.

Feng J, Tang D, Wang J, Zhou Q, Peng J, Lou H, Sun Y, Cai Y, Chen H, Yang J, Liu P, Wang L, Zou J. Feng J, et al. Among authors: sun y. Clin Cancer Res. 2022 Dec 15;28(24):5297-5305. doi: 10.1158/1078-0432.CCR-22-0346. Clin Cancer Res. 2022. PMID: 35653122 Clinical Trial.

2

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, Cristofanilli M, Ning Z, Lu X. Jiang Z, et al. Among authors: sun t, sun y. Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27. Lancet Oncol. 2019. PMID: 31036468 Clinical Trial.

3

ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer.

Li J, Gao A, Zhang F, Wang S, Wang J, Wang J, Han S, Yang Z, Chen X, Fang Y, Jiang G, Sun Y. Li J, et al. Among authors: sun y. Cancer Lett. 2021 Mar 31;501:263-276. doi: 10.1016/j.canlet.2020.10.048. Epub 2020 Nov 3. Cancer Lett. 2021. PMID: 33152402

4

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.

Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, Chang GC, Lu Y, Pan H, Chiu CH, Wang Z, Feng J, Zhou J, Xu X, Guo R, Chen J, Yang H, Chen Y, Yu Z, Shiah HS, Wang CC, Yang N, Fang J, Wang P, Wang K, Hu Y, He J, Wang Z, Shi J, Chen S, Wu Q, Sun C, Li C, Wei H, Cheng Y, Su WC, Hsia TC, Cui J, Sun Y, Ou SI, Zhu VW, Chih-Hsin Yang J. Lu S, et al. Among authors: sun c, sun y. J Thorac Oncol. 2022 Mar;17(3):411-422. doi: 10.1016/j.jtho.2021.10.024. Epub 2021 Nov 19. J Thorac Oncol. 2022. PMID: 34801749 Free article.

5

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.

Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. Lu S, et al. Among authors: sun m, sun c, sun y. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. doi: 10.1200/JCO.21.02641. Epub 2022 May 17. J Clin Oncol. 2022. PMID: 35580297 Free PMC article. Clinical Trial.

6

Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.

Zhou Q, Zhao J, Chang J, Wang H, Fan Y, Wang K, Wu G, Nian W, Sun Y, Sun M, Wang X, Shi H, Zheng X, Yao S, Qin M, Shen Z, Yang J, Wu YL. Zhou Q, et al. Among authors: sun m, sun y. Cancer. 2023 Oct 15;129(20):3239-3251. doi: 10.1002/cncr.34897. Epub 2023 Jun 6. Cancer. 2023. PMID: 37282666 Free article.

7

ILT4 facilitates angiogenesis in non-small cell lung cancer.

Wang S, Wang J, Gong W, Zhang F, Chen X, Xu H, Han Y, Fu X, Wang L, Li J, Gao A, Sun Y. Wang S, et al. Among authors: sun y. Cancer Sci. 2024 May;115(5):1459-1475. doi: 10.1111/cas.16126. Epub 2024 Mar 3. Cancer Sci. 2024. PMID: 38433526 Free PMC article.

8

PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data.

Ge Y, Zhan Y, He J, Li J, Wang J, Wei X, Wang C, Gao A, Sun Y. Ge Y, et al. Among authors: sun y. J Cancer Res Clin Oncol. 2024 Mar 18;150(3):135. doi: 10.1007/s00432-024-05637-1. J Cancer Res Clin Oncol. 2024. PMID: 38499838 Free PMC article.

9

Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study.

Zhang J, Gao A, Wang S, Sun Y, Wu J, Wang D, Ge Y, Li J, Sun H, Cheng Q, Sun Y. Zhang J, et al. Among authors: sun y, sun h. Respir Res. 2024 Jun 21;25(1):256. doi: 10.1186/s12931-024-02890-3. Respir Res. 2024. PMID: 38907273 Free PMC article.

10

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).

Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Weng J, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Wei H, Wei J, Zhang Z, Wu Q. Lu S, et al. Among authors: sun m, sun y. Cancer Commun (Lond). 2024 Sep;44(9):1005-1017. doi: 10.1002/cac2.12594. Epub 2024 Jul 17. Cancer Commun (Lond). 2024. PMID: 39016053 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64,480 results

Search Page

Filters